Company News: Novartis

Share this article:
At a meeting this week, Novartis said it plans to submit cancer compounds Tasigna, for initial therapy in patients with chronic myeloid leukemia (CML), and Zometa, for patients with breast cancer, to the FDA by year's end. Novartis could make several other oncology submissions next year, including one for kidney cancer drug Afinitor, pending the outcome of ongoing clinical trials. In results of one trial, unveiled a day before the meeting, Novartis said Tasigna showed improvement over Gleevec among early-stage leukemia patients. Tasigna is already marketed for the minority of CML patients who are resistant to Gleevec, which is set to lose patent protection starting in 2015. "We have a productive and innovative pipeline that holds promise for many patients," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division.
 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.